Pharmacologic management of the patient with type 2 diabetes

Nurs Clin North Am. 2001 Jun;36(2):217-42, vi.

Abstract

The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that the benefit of optimal glucose control in type 2 diabetes is a significant reduction in diabetes-related complications. In addition, the UKPDS also demonstrated that type 2 diabetes is a progressive disorder. Whereas many patients may initially receive good glucose control from a single medication, they are likely to require multiple medications to maintain this same level of glucose control as the disease progresses. The recent introduction of several new classes of glucose-lowering medications has allowed health care providers to explore the use of these medications alone and in combination to help patients with type 2 diabetes maintain optimal glucose control. Therefore, it is important to understand the physiologic actions, benefits, and risks of these medications in the treatment of type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Blood Glucose / analysis
  • Blood Glucose / drug effects
  • Combined Modality Therapy
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • Disease Progression
  • Drug Interactions
  • Humans
  • Hypoglycemic Agents / classification
  • Hypoglycemic Agents / metabolism
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Resistance
  • Patient Selection
  • Treatment Outcome

Substances

  • Blood Glucose
  • Hypoglycemic Agents